Development of novel thiazolidine-2,4-dione derivatives as PPAR-γ agonists through design, synthesis, computational docking, MD simulation, and comprehensive <i>in vitro</i> and <i>in vivo</i> evaluation

Gowdru Srinivasa, Mahendra; B. C., Revanasiddappa; Prabhu, Ashwini; Rani, Vinitha; Ghate, Sudeep D.; Kumar B. R., Prashantha

doi:10.1039/d3md00273j

RSC Med. Chem.

2023

DOI: 10.1039/d3md00273j

|View full text |Cite

Development of novel thiazolidine-2,4-dione derivatives as PPAR-γ agonists through design, synthesis, computational docking, MD simulation, and comprehensive in vitro and in vivo evaluation

Mahendra Gowdru Srinivasa,

Revanasiddappa B. C.,

Ashwini Prabhu

et al.

Abstract: The present study was conducted to develop new novel 2,4-thiazolidinedione derivatives (3h–3j) as peroxisome proliferator-activated receptor-γ (PPAR-γ) modulators for antidiabetic activity.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Design, synthesis of new 2,4-thiazolidinediones: In-silico, in-vivo anti-diabetic and anti-inflammatory evaluation

Gharge,

Alegaon,

Ranade

et al. 2024

European Journal of Medicinal Chemistry Reports

View full text Add to dashboard Cite

Design, synthesis of new 2,4-thiazolidinediones: In-silico, in-vivo anti-diabetic and anti-inflammatory evaluation

Gharge,

Alegaon,

Ranade

et al. 2024

European Journal of Medicinal Chemistry Reports

View full text Add to dashboard Cite

Extraction, isolation, structural analysis, PPAR-γ binding studies & transactivation, glucose uptake, lipid lowering activity and in silico studies of Pterocarposide, Sabioside and Pterostilbene

Susil,

Harindranath,

Rajeshwari

et al. 2025

Journal of Molecular Structure

View full text Add to dashboard Cite

Novel rhodanine–thiazole hybrids as potential antidiabetic agents: a structure-based drug design approach

Gharge,

Alegaon,

Ranade

et al. 2025

RSC Med. Chem.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Development of novel thiazolidine-2,4-dione derivatives as PPAR-γ agonists through design, synthesis, computational docking, MD simulation, and comprehensive in vitro and in vivo evaluation

Abstract: The present study was conducted to develop new novel 2,4-thiazolidinedione derivatives (3h–3j) as peroxisome proliferator-activated receptor-γ (PPAR-γ) modulators for antidiabetic activity.

Cited by 4 publications

References 36 publications

Design, synthesis of new 2,4-thiazolidinediones: In-silico, in-vivo anti-diabetic and anti-inflammatory evaluation

Design, synthesis of new 2,4-thiazolidinediones: In-silico, in-vivo anti-diabetic and anti-inflammatory evaluation

Extraction, isolation, structural analysis, PPAR-γ binding studies & transactivation, glucose uptake, lipid lowering activity and in silico studies of Pterocarposide, Sabioside and Pterostilbene

Novel rhodanine–thiazole hybrids as potential antidiabetic agents: a structure-based drug design approach

Contact Info

Product

Resources

About